Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo A Ascierto

Showing results (1-10 of 470) with videos related to

Pageof 47
Sort By:
Cancer Immunology, Immunotherapy : CII|January 1, 2015
Immunotherapies and novel combinations: the focus of advances in the treatment of melanomaPaolo A Ascierto
Melanoma Management|September 8, 2018
Combination therapies in advanced melanomaPaolo A Ascierto
The New England Journal of Medicine|October 5, 2012
MEK inhibition in BRAF-mutated melanomaPaolo A Ascierto
Melanoma Management|September 8, 2018
Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMRPaolo A Ascierto
Tumori|February 8, 2014
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studiesPaolo A Ascierto
Melanoma Management|September 8, 2018
Anti-PD-1 and PD-L1 antibodies in metastatic melanomaEster Simeone, Paolo A Ascierto
Journal of Immunotoxicology|April 25, 2012
Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1Ester Simeone, Paolo A Ascierto
Cancer|March 1, 2014
Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanomaPaolo A Ascierto, Kim Margolin
Journal for Immunotherapy of Cancer|December 1, 2022
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinomaPaolo A Ascierto, Dirk Schadendorf
Melanoma Management|September 8, 2018
Advances in immunotherapy for melanomaPaolo A Ascierto, James Larkin
Pageof 47

Showing results (1-10 of 470) with videos related to

Sort By:
Pageof 47
Cancer Immunology, Immunotherapy : CII|January 1, 2015
Immunotherapies and novel combinations: the focus of advances in the treatment of melanomaPaolo A Ascierto
Melanoma Management|September 8, 2018
Combination therapies in advanced melanomaPaolo A Ascierto
The New England Journal of Medicine|October 5, 2012
MEK inhibition in BRAF-mutated melanomaPaolo A Ascierto
Melanoma Management|September 8, 2018
Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMRPaolo A Ascierto
Tumori|February 8, 2014
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studiesPaolo A Ascierto
Melanoma Management|September 8, 2018
Anti-PD-1 and PD-L1 antibodies in metastatic melanomaEster Simeone, Paolo A Ascierto
Journal of Immunotoxicology|April 25, 2012
Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1Ester Simeone, Paolo A Ascierto
Cancer|March 1, 2014
Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanomaPaolo A Ascierto, Kim Margolin
Journal for Immunotherapy of Cancer|December 1, 2022
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinomaPaolo A Ascierto, Dirk Schadendorf
Melanoma Management|September 8, 2018
Advances in immunotherapy for melanomaPaolo A Ascierto, James Larkin
Pageof 47